Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate dry eye patients based on the Report of International Dry Eye Workshop (DEWS)~* OSDI score between 12 and 45~* Provided informed consent~Exclusion Criteria:~* Patients with one blind eye~* Visual acuity of 20/100 or worst in any eye~* Patients with any active ocular disease that would interfere with study interpretation~* Patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol~* Patients with history of hypersensitivity or contraindication for any drug used in the study~* Contact lens users~* Pregnant patients, at risk of pregnancy or breastfeeding~* Patients without birth control treatment~* Patients who had participated in any clinical trial in the last 90 days~* Legal or mentally disabled patients who could not give informed consent~* Patients who do not provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRO-148 (Type: EXPERIMENTAL): PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day
- Systane® (Type: ACTIVE_COMPARATOR): Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day

Based on this trial design, predict the completion outcome and termination type (if applicable).